Back
 WJA  Vol.4 No.3 , September 2014
Immunovirologic Evaluation of Triomune (Lamivudine, Stavudine and Nevirapine) Antiretroviral Therapy in First Line HIV-1 Adult Patients in N’Djamena, Chad
Abstract: Contexte: The fight against HIV/AIDS epidemics is one of the greatest challenges of this century. The epidemic affects generally under-developed countries, and Sub-Saharan Africa are the most concerned. The combined marketed form known as Triomune was used as first-line treatment in several sub-Saharan African Countries (60% of VIH infected people), including Chad. However, no evaluation has been done for that treatment in the country. Objective: To evaluate the efficacy and safety immuno-virological of Triomune at the General Hospital in N’Djamena/Chad. Methods: 48 HIV-1 positive patients eligible for ARV treatment were enrolled in our study, and they have been then followed for 8 months. We have measured in these patients the CD4 cell count before treatment and at the 8th month of treatment. After 8 months of treatment, we have also evaluated the Lymphocyte T CD4 and the plasma viral load (VL). Comparisons of means of CD4 lymphocytes and plasma CV (≥1000 copies/ml) were used to define treatment failure. Results: 48 patients were under Triomune regime. The average CD4 count was decreased from 462 ± 179.22 [56 - 981] cells/mm3 before treatment to 327.23 ± 153.77 [10 - 1008] cells/mm3 at the 8th month of treatment. The mean plasma viral load for patients was 66008.62 copies/ml. The failure rate to Triomune was 43.75% (21/48). Conclusion: Aside from the side effects already described for Triomune, our study reveals a high treatment failure rate. Hence, there is the need of regular revisions of therapeutic regime administer in the first intention.
Cite this paper: Adawaye, C. , Erick, K. , Djibrine, S. , Chahad, A. , Moussa, A. , Bertin, T. , Dolores, V. and Michel, M. (2014) Immunovirologic Evaluation of Triomune (Lamivudine, Stavudine and Nevirapine) Antiretroviral Therapy in First Line HIV-1 Adult Patients in N’Djamena, Chad. World Journal of AIDS, 4, 301-305. doi: 10.4236/wja.2014.43035.
References

[1]   ONUSIDA, Rapport Mondial (2012) Rapport ONUSIDA sur l’épidémie mondiale de sida. JC2417 Fconsulté en Novembre 2012. http://www.unaids.org

[2]   Bandoumal, O., Kostelngar, N., Tchobkreo, B., Madnodji, R., et al. (2005) Enquête Nationale de prévalence de l’infection à VIH au Tchad. Institut National de la Statistique, des Etudes Economiques et Démographiques, INSEED, 2005.

[3]   Lihana, R.W., Ssemwanga, D., Abimikua, A. and Ndembi, N. (2012) Update on HIV-1 Diversity in Africa: A Decade in Review. AIDS Reviews, 14, 83-100.

[4]   Vidal, N., Koyalta, D., Richard, V., Lechiche, C., Ndinaromtan, T., Djimasngar, A., Delaporte, E. and Peeters, M. (2003) High Genetic Diversity of HIV-1 Strains in Chad, West Central Africa. Journal of Acquired Immune Deficiency Syndromes, 33, 239-246.
http://dx.doi.org/10.1097/00126334-200306010-00020

[5]   Hamers, R.L., Derdelinckx, I., van Vugt, M., Stevens, W., Rinke de Wit, T.F. and Schuurman, R. (2008).The Status of HIV-1 Resistance to Antiretroviral Drugs in Sub-Saharan Africa. Antiviral Therapy, 13, 625-639.

[6]   Koyalta, D., Charpentier, C., Beassamda, J., Rey, E., Si-Mohamed, A., Djemadji-Oudjeil, N. and Belec, L. (2009) High Frequency of Antiretroviral Drug Resistance among HIV-Infected Adults Receiving First-Line Highly Active Antiretroviral Therapy in N’Djamena, Chad. Clinical Infectious Diseases, 49, 155-159. http://dx.doi.org/10.1086/599611

[7]   Garcia, M.V., Mukeba-Tshialala, D., Vaira, D. and Moutschen, M. (2009).Triomune: La Thérapie du pauvre? Revue Médicale de Liège, 64, 30-44.

[8]   Integrated Regional Information Networks (IRIN), AFRIQUE (2010) L’échec thérapeutique trop souvent mal détecté. consulté de Novembre 2012. http://www.irinnews.org/fr

[9]   WHO (2006) Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Recommendations for a Public Health Approach. Revisions. 2006. Consulté en Novembre 2012. www.who.int/hiv/pub/guidelines

[10]   Ministère de la santé publique. Programme national de lutte contre le Sida (2006) Guide national de prise en charge de l’infection par le VIH. Ministère de la Santé Publique/Programme National de Lutte contre le Sida (PNLS).

[11]   Lowe, S.H., Hassink, E.A., Van Eck-Smit, B.L., Borleffs, J.C., Lange, J.M. and Reiss, P. (2007) Stavudine but Not Didanosine as Part of HAARR Contributes to Péripherallipoatrophy: A Substudy from Antiretroviral Regimen Evaluation Study (ARES). HIV Clinical Trials, 8, 337-344.

[12]   Tapsfield, J., Mathews, T., Lungu, M. and van Oosterhout, JJ. (2011) Underreporting of Side Effects of Standard First-Line ART in the Routine Setting in Blantyre, Malawi. Malawi Medical Journal, 23, 115-117.

[13]   Organisation Mondiale de la Santé (2009) Recommandations rapides pour la prise en charge de l’infection par le VIH de l’adulte et de l’adolescent dans les pays à ressources limitées. OMS, Genève.

 
 
Top